Clinical Trial Search

Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…

Primary: Number of Participants Who Were Cured — 120; 130 Participants — p=<0.001

Primary: Number of Subjects With Combined Clinical and Microbiologic Response — 70 Participants

Primary: Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy — 111; 122 Participants

Primary: Participants With Urine Cultures With Bacteriuria (>100,000 Cfu/ml or >=100,000 Cfu/ml) Plus Pyuria (Any WBC) — 26; 32; 21; 27 participants

Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as…

Primary: Number of Participants With a Catheter Associated Urinary Tract Infection (CAUTI) — 7; 6 Participants

Primary: Post-operative Urinary Tract Infection — 19; 20 Participants

Primary: Number of Participant With Urinary Tract Infection — 12; 13 Participants

Primary: Urinary Tract Infection — 11; 12 UTI

Primary: Urinary Tract Infections — 18; 10 participants

Primary: Incidence of Urinary Tract Infection — 7; 13 participants

Primary: Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success — 62.6; 36.0 percentage of participants

Primary: Number of Participants Experiencing Urinary Tract Infection Within 6 Weeks of Surgery — 13; 13 Participants — p=0.97

Primary: Urinary Tract Infection After Percutaneous Nephrostomy Procedure — 5; 10 Percutaneous nephrostomy procedure — p=0.548

Primary: Number of Urine Cultures Collected Out of the Total Number Expected to be Collected. — 81; 74; 85; 73 Urine cultures

Primary: Incidence of Urinary Track Infection (UTI) — 62; 71 Participants

Primary: Occurrence of Urinary Tract Cancer — 0.73; 1.07; 1.34; 1.52 Events per 1000 patient years — p=0.122

Primary: Number of Patients With Adverse Events During and After FMT — 1 Participants

Primary: Changes to the Urinary Microbiota — 3; 2; 1 participants

Primary: Eligible Subjects That Were Enrolled in the Study — 70 Participants

Primary: Change in Vaginal Microbiota — 2.75 change in percent relative abundance

Primary: Clinical Cure — 140; 123; 10; 27 participants

Primary: Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI — 101; 119 days

Primary: Participants With Clinically-diagnosed and Treated UTI's. — 15; 30 participants

Primary: Favorable Clinical Outcomes (FCl) — 170; 132 Participants

Primary: UTI Incidence as Described Below, Over the 16 Week Study Period Following Randomization, in the LACTIN-V Treatment Group (Group A) as Compared to the Placebo Group…

Primary: The Number of Patients Receiving Appropriate Treatment — 44; 29 Participants

Primary: Clinical Validation of Biosensor Assays Used for Pathogen Identification and Antimicrobial Susceptibility Testing in Patients at Risk of Urinary Tract Infections. — 89…

Primary: Treatment of Clinically Suspected UTI - Using Intent to Treat Analysis — 13; 12 Participants